Extending Treatment: Injectable Long-Acting Buprenorphine | Andrew Herring, MD

This presentation is part of the 2020 State of the Art in Addiction Medicine conference which covers an expansion of treatment into correctional health, hospital consultation services and emergency rooms. It will cover how, despite the pandemic, telehealth can reach those who are isolated. It will address the worrisome trends in fentanyl, methamphetamine, tobacco and benzodiazepines use; legalization of cannabis, treatment updates for youth, cannabis and alcohol in pregnant women; and novel treatments such as non-benzodiazepines for alcohol withdrawal and psychedelics for substance use disorders.  

Learners cannot sign up for individual lectures, only for the full 2020 State of the Art in Addiction Medicine. Please contact CSAM (csam@csam-asam.org) if you have any questions about this online educational offering. 

Target Audience

Addiction medicine specialists who want an overview of the latest developments in the field and their relevance to clinical practice

  1. Primary care, psychiatry and other specialty field clinicians who want a better understanding of addiction and to improve their care of patients with unhealthy substance use
  2. Public policy makers, administrators and advocates who want an understanding of the current state of the field of addiction and its grater implications including towards prevention, access to care, integrated systems of care and healthcare technology
  3. Other healthcare professionals, including psychologists, therapists, nurses, and addiction counselors, who are involved in the treatment of patients with or at risk of substance use

Learning Objectives

  • Interpret pharmacokenetic data on intravenous, sublingual and extended release subcutaneous buprenorphine.
  • Describe specific case histories of emergency department patients treated with extended release subcautaneous buprenorphine.
Course summary
Available credit: 
  • 0.75 AMA Category 1
  • 0.75 Attendance
Course opens: 
Course expires: 

Andrew A. Herring, MD

Dr. Andrew A Herring graduated from Harvard Medical School and completed residency in emergency medicine at Highland Hospital—Alameda Health System in Oakland, CA where he continues as an attending emergency physician and Director of Research. He is also Medical Director of the Highland Bridge Program and Substance Use Disorder Program. Dr. Herring’s current research focuses on emergency department treatment of opioid use disorders and pain management. He is an active researcher within the NIDA Clinical Trials Network and Lead investigator for NIDA CTN-0069-A-1 and a co-investigator NIDA CTN 0099 (ED-INNOVATION). Dr. Herring is a Principle Investigator with the California BRIDGE Program and an Assistant Clinical Professor at the University of California, San Francisco. He has conducted health policy research as a Fulbright Scholar in Central America. Dr. Herring is board-certified in Emergency Medicine, and Addiction Medicine, and Pain Medicine.

DISCLOSURE: No relevant financial relationships to disclose

The California Society of Addiction Medicine (CSAM) is accredited by the California Medical Association to provide continuing medical education for physicians. CSAM takes responsibility for the content, quality and scientific integrity of this CME activity.

CSAM designates this live educational activity for a maximum of 0.75 AMA PRA Category 1 Credits™, Physicians should only claim credit commensurate with the extent of their participation in the activity. 

Continuing education credit is available for psychologists, therapists, substance use counselors, nurses and physician assistants.

(see additional information on page for parent course)

Available Credit

  • 0.75 AMA Category 1
  • 0.75 Attendance


Please login or register to take this course.